the hemostasis community in 1995. 2, 3 The original reports contained detailed descriptions of the instrument and some preliminary test data.
Then, as now, the system requires aspiration of a blood sample in a reservoir, under constant vacuum, through a capillary and a microscopic aperture cut into a test membrane. Separate cartridge membranes contain collagen and epinephrine (C/Epi) or adenosine 5 0 -diphosphate (C/ADP). These platelet agonists, and the generated high shear rates, result in platelet attachment, activation, aggregation, and eventually a stable platelet plug at the aperture that causes occlusion of the aperture (reported as the "closure time"; CT).
1998 perhaps represents the historical turning point for the PFA-100, with publication of several seminal papers on detection of von Willebrand disease (VWD) and platelet disorders, including desmopressin (DDAVP) and von Willebrand factor (VWF) concentrate therapy. [4] [5] [6] The PFA-100 was reportedly more sensitive than the skin bleeding time (SBT), both to VWD detection and therapeutic monitoring. Similar clinical sensitivities and specificities were also reported in regards to "platelet function" compared to classical platelet aggregometry. 5 Other 1998 publications described use in the pediatric population, pregnant women, and in non-human settings, as well as its inaugural mention in a review. 6 The PFA-100 continued to gather interest over subsequent decades, today featuring in almost 1000 publications and over 50 reviews, including several by this author. The PFA-100 has recently been "upgraded" to a "PFA-200," which has transformed the user interface and electronic management, but retained the fundamental mechanics, and essentially provides the same results. 7 Although a fairly simple conceptual device, the PFA-100/200 has become an important tool in clinical hemostasis diagnostics, and is now widely utilized by scientists and clinical researchers. This current mini-review is meant to summarize an extensive literature into a short synopsis of its main clinical utility.
| G E N E R A L C O NS I D E RA T I O N S -PR E-A N AL YTIC AL A N D A N A LY TICA L
Classical platelet "activity" testing (ie, "platelet aggregation," or "platelet function studies," PFS) is highly labor-intensive and technically skilled. 8 Typically utilizing platelet aggregometry with whole blood or platelet rich plasma (PRP), with resulting platelet adhesion and/or aggregation assessed after "challenge" using various plateletagonists. Additional intensive investigations (eg, platelet release, activation, storage) studies may also be performed. Similarly, comprehensive investigation of VWD requires extensive testing with a plethora of laboratory tests. 9 However, comprehensive PFS and VWD investigations are not always immediately available or indicated, so the PFA-100/200
provides an alternative to, or supplements these in select circumstances (summarized in Figure 1A and Summary Table) . The PFA-100/200
gives a single CT end-point reading, with a theoretical maximum of 300 sec; however, values reported as >250 sec are considered "maximally" prolonged. The PFA-100/200 is sensitive to many hemostatic defects and drug effects, but also to platelet deficiencies and hematocrit disturbances. C/Epi tends to be most sensitive, usually yielding longer CTs than C/ADP. The degree of CT prolongation, and the resulting C/Epi vs. C/ADP test pattern, helps identify severity of potential hemostatic disorders and likelihood of drug-related effects ( Figure 1B ).
Blood is collected into sodium citrate anticoagulant, and should be quickly transported to the instrument, at ambient temperature (ie, 15-258C), avoiding use of refrigeration or pneumatic tube systems, and the test completed within 5 h of collection. 6 Samples must not be centrifuged, and cannot be tested after centrifugation/resuspension, because platelet activation will occur. CTs are not generally influenced by gender or oral contraceptive use, but may be affected by age and smoker status. 6 Shorter CTs are evident in pregnancy, and ABO blood group effects are also evident, 6 as is circadian variation, 10 with CTs being shortest at times of normal awaking (8 AM), an effect possibly driven by plasma VWF. Perhaps most relevant is the effect of hematocrit and platelet count; low hematocrits, platelet counts, and/or leucocyte counts can all yield CT prolongation. 6 Thus, an "abnormal" CT will not invariably reflect a primary hemostatic disorder. The CT is not affected by defects/deficiencies in fibrinogen or other coagulation factors (including VIII, IX, and XI), and not therefore useful for assessing secondary hemostasis (eg, hypofibrinogenaemia, dysfibrinogenaemia, hemophilia). CTs are not influenced by heparin, unless very high, nor by vitamin K antagonist therapy, or by the newer direct oral anticoagulants. 6, 11 Another important consideration is test reproducibility. One study employing 120 well characterized normal individuals raised some concerns, since "differences between duplicate measurements exceeded 15%," and thereby suggested that laboratories perform the test in duplicate. 12 In our experience, routine duplicate testing is unnecessary, with reproducibility generally with 20%. However, repeat testing for confirmation is recommended whenever an unexpected abnormal CT is determined in a new patient, or if there is a mismatch between CTs obtained with C/Epi vs. C/ADP.
| C L I N I C A L U T IL I T Y OF CT S F O R IDENTIFICATION AND TREAT MENT OF P R I M A R Y HE M O S T A S I S D I S O R D E R S
There have been many studies assessing sensitivity to primary hemostasis disorders, including the effect of therapy, as previously extensively reviewed. 6 
| High sensitivity to VWF and VWD
The PFA-100/200 is very sensitive to level and function of plasma VWF, with very strong inverse relationships between CTs and VWF parameters (especially functional VWF, as measured by activity assays such as collagen binding; VWF:CB). 6 Thus, prolonged CTs will arise when VWF is low or absent (ie, VWD), but conversely be short when levels are high. This relationship also has a strong (but generally underrecognized) influence on drug (eg, aspirin) sensitivity. 13 Thus, high plasma levels of VWF can mask the presence of aspirin, leading to normal CTs in patients taking aspirin.
In early studies, PFA-100/200 CTs were identified consistently as more sensitive than the SBT to VWD. Combined studies have now assessed over 600 individuals with VWD and over 1000 normal individuals. 6 Overall VWD sensitivity is around 85-90%, with sensitivity to type 1 VWD being related to plasma VWF level; thus, levels <25%, being more likely to reflect true congenital (VWF mutation associated)
VWD are almost invariably associated with prolonged CTs, whereas levels above 30%, being less likely to reflect "true VWD," potentially giving abnormal or normal CTs. However, all VWD of type 3, platelettype ("pseudo"), and type 2A (representing those with relative loss of high molecular weight (HMW) VWF), give abnormal CTs, as do "most" type 2B and 2M VWD cases. Indeed, normal CTs in these latter circumstances are rare, suggesting either unusual cases or more likely case misidentification. 14 As expected, the PFA-100/200 is not sensitive to type 2N VWD, given that a low plasma FVIII level represents the major phenotypic presentation, unless of a composite subtype that also expresses low VWF levels.
Sensitivity to VWD was most strikingly and recently conveyed 15 by the same French group that published initial findings in 1998, 4 but now reflecting on 16 years experience, and reporting that CTs were more effectively able to identify VWD than the ristocetin cofactor (VWF:RCo) assay, otherwise considered the gold standard VWF activity assay.
However, it does need to be clarified that some groups have found less impressive findings in terms of "VWD," especially "Type 1."
For example, Quiroga et al. 16 reported that PFA-100 CTs had low sensitivity to screen 148 consecutive patients with hereditary mucocutaneous hemorrhages including "VWD." However, a review of their data would show that most of these patients only expressed mildly reduced levels of VWF, which although certainly reflecting a risk factor for bleeding, would likely not reflect a congenital VWD. 17 On the other hand, a similarly interesting study by Veyradier et al., investigating 70
women with menorrhagia, 18 identified prolonged CTs in all six patients with VWF levels < 50%. In total, published studies have assessed over 300 individuals with various congenital platelet disorders and over 700 normal individuals. 6 As for VWD, there is broad agreement in terms of key findings, with highest sensitivity to severe cases (eg, Glanzmann Thrombasthenia and Bernard Soulier Syndrome). However, data for milder platelet disorders (eg, storage pool deficiencies and secretion defects) is more varied and reflects poorer sensitivity, with around only half such cases giving abnormal C/Epi CTs, and less (around a quarter) giving abnormal C/ ADP CTs. In contrast to VWD, platelet function disorder sensitivity is reportedly similar to SBT. Irrespective, given relative insensitivity to mild disorders, CTs cannot be recommended to screen for such disorders.
| Monitoring treatment for VWD
6,21
3.4 | Utility for monitoring treatment in platelet function defects?
DDAVP therapy is useful clinically for some "mild" platelet disorders, generally increasing VWF, normalizing C/Epi CT, and shortening C/ ADP CT. 6 However, like VWD, lack of CT correction does not necessarily reflect treatment failure.
| Clinical utility for assessing surgical bleeding risk?
This is a poorly investigated possible indication, and where investigated has provided conflicting information. Impressively, Koscielny et al. 22, 23 reported large studies and concluded that use of standardized questionnaires and, if indicated, C/Epi CT and/or other specific tests (eg, VWF testing), ensured detection of impaired hemostasis in advance of surgical procedures. Also, patients preoperatively identified as having impaired primary hemostasis (including platelet dysfunction and VWD) and then pretreated, were able to reduce their need for homologous blood transfusions.
However, other studies assessing bleeding risk in various settings have provided less convincing and contradictory results. 6 For example,
Gopalakrishnan et al. recently reported a large retrospective medical
records-based study, including 497 patients who also had platelet aggregation testing, and reporting correlation of abnormal spontaneous and/or procedure-related bleeding impaired platelet aggregation or release in response to several agonists, but not with PFA CTs, or even with the results of VWF and platelet flow-cytometry tests. 24 However, it is probable that most of these were medication related or acquired events.
In summary, this author believes there is little value in assessing
CTs on pre-surgical patients without formal pre-operative assessment of medication and family/personal bleeding history ( Figure 1A ), but even despite this, CTs will not always provide comparative data, depending on the patient or patient population under investigation (eg, comparative inclusion/exclusion of VWD, platelet defects, medications, co-morbidities, and illnesses).
In terms of mucocutaneous bleeding, the perceived utility of CTs will also depend on the study population. CTs will generally be abnormal in "true" VWD (ie, type 1 with VWF levels <25 U/dL, and types 2A, 2M, and 2B VWD), as well as in severe platelet disorders. However, CTs may be normal or abnormal in milder disorders, including individuals with "low VWF" as a risk factor for bleeding, and those with mild platelet function disorders.
| S E N S IT I V I T Y OF CT S T O M E D I C AT IO N S / D R U G E F F E C T S-M O N I T O R IN G VS. A N A LY T I C A L VA R I AB LE ?
Many drugs influence CTs. Accordingly, the PFA-100 has been exten- influence CTs (eg, due to raised VWF [25] [26] [27] [28] ). Indeed, several other instruments, including the Multiplate and VerifyNow, probably have better (if similarly, imperfect) utility for such purpose.
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| C L I N I C A L U T IL I T Y OF CTS FOR A N Y T H I N G E LS E ?
Recalling the PFA-100/200 has featured in so many publications, there may be several other potential applications. The PFA-100/200 has for example been investigated for effects of many "non-medication" compounds, including alcohol, cocoa/chocolate, garlic, and a range of herbal "medicines." 6 Of interest, especially given that both cocoa/chocolate and alcohol maybe somewhat protective against cardiovascular disease, both have been shown to prolong CTs.
CTs have also been evaluated within the context of many disease states (eg, pre-eclampsia in pregnancy, in the context of air pollution, and renal and liver disease). Perhaps of most current interest is the concept that short CTs may reflect increased thrombosis risk, both in and outside the context of anti-platelet therapy. 6 Whether such short CTs are reflective of heightened platelet reactivity, elevated levels of VWF, something else, or a combination of factors, remains unclear.
However, elevated plasma VWF leads to shortening of CTs and is itself a risk factor for thrombosis. A recommended algorithm for the use of CTs in screening hemostatic disturbances is given in Figure 1 , and an overall summary of clinical utility provided in Summary The closure time (CT) is a test for primary hemostasis, and is sometimes referred to as an "in vitro" bleeding time.
How is it measured?
The CT is performed using a special instrument, either the PFA-100 (original model) or the PFA-200 ("upgraded" model; not available in all geographies, including the USA). There are currently three test cartridges available, each containing several platelet agonists, and abbreviated here as C/Epi (collagen/epinephrine), C/ADP (collagen/adenosine diphosphate), and P2Y12 (this one is specifically for measuring sensitivity to clopidorel, and is not available in all geographies, including the USA). Essentially, the operator pipettes a small volume (usually 800 uL) of whole blood (sodium citrate anticoagulated; as per normal "blue-top" coagulation tube) into the reservoir of the test cartridge and the test is initiated on the instrument. The instrument then aspirates the blood sample through a capillary, eventually coming into contact with platelet agonists present on a membrane; these activate the patient's platelets, causing platelet adhesion and aggregation and eventual occlusion of the capillary; this event is measured in seconds and called the CT.
What are the normal range values?
Although these should be established or verified at each test site, the current manufacturer recommended ranges (71-118 and 85-165 respectively for C/ADP and C/Epi) are not dissimilar to most ranges reported in the literature, 1 including our own (67-127 and 94-162, respectively).
What conditions or types of conditions is it used for?
The PFA CT is used as a screening test to identify the potential presence of primary hemostasis disorders, such as von Willebrand disease (VWD), or else to exclude such disorders.
The CT is very sensitive to the presence or absence of von Willebrand factor (VWF), especially the functional or high molecular weight (HMW) forms, as well as to platelets (number and activity), and also hematocrit and anti-platelet agents such as aspirin. CT values can therefore be used to exclude severe VWD or severe platelet dysfunction (if C/Epi (and C/ADP) CT is normal). Abnormal PFA CTs are less useful, potentially identifying a primary hemostasis disorder, or a thrombocytopenia/low hematocrit, or anti-platelet therapy (possibilities that will then need by review of patient medications or additional tests in order to be specifically defined).
What tests are helpful to do with it for a more complete picture?
The initial investigation of an abnormal CT will be a review of patient medications plus a complete blood count (CBC), which will identify the presence or absence of a low platelet count, perhaps some platelet morphological features, plus the hematocrit. If these are all normal, and medication effects can be excluded, as well as exclusion of other potential influences such as herbal supplements (etc) and pre-analytical events, then further specific testing for VWD (various VWF related tests 2 ) and then full platelet function testing by aggregometry or other method.
)
What tests provide similar information?
A skin bleeding time (SBT) would provide similar information, but this test is no longer recommended in developed countries, because it is invasive, shows greater variability, and also poorer sensitivity, at least to VWD.
What tests can be avoided/eliminated?
The PFA CT is a screening test of primary hemostasis, in a similar way that the APTT is a screening test of secondary hemostasis. It can be performed rapidly and in urgent situations, and at sites where specialized testing (eg, performed for full investigation of VWD or platelet function) may not be available or cannot provide the same timely result. Thus, it can replace those tests if CT results have been found to be normal, and the pre-test probability of having those disorders is low, with the caveat that the PFA CT is not sensitive for mild platelet disorders or "mild VWD." This may be particularly useful in smaller labs with limited access to more sophisticated hemostasis testing.
How does its use impact treatment?
In urgent test situations, clinicians and surgeons may feel reassured that patients do not have severe primary hemostasis defects, and can thus progress surgical procedures safely. In some cases, testing can help firm up the type of VWD as well as the best therapeutic approach to individual patients, since treatment of primary hemostasis disorders or VWD types may differ accordingly. However, like the APTT, CTs do not normally impact treatment directly, but instead help guide the process for further patient follow-up, eventual diagnosis or exclusion of particular defects, and thus eventual optimal treatments.
